Alcon Reports Results for Dry-Eye-Treatment Trials
By Denny Jacob
Alcon reported topline results from two trials evaluating AR-15512, a candidate treatment for dry-eye disease.
The eye-care company said the primary endpoint achieved statistical significance in both trials. Additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production, said Alcon.
AR-15512 was well tolerated and no serious ocular adverse events were reported.
Alcon expects to file a new drug application for AR-15512 with the U.S. Food and Drug Administration in mid-2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 09, 2024 17:05 ET (22:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?